
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="67D714F789B756931C14F70020219E94.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="discon">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334396/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Discover Oncology">
<meta name="citation_title" content="Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series">
<meta name="citation_author" content="Qingyu Xu">
<meta name="citation_author_institution" content="Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China">
<meta name="citation_author" content="Bin Leng">
<meta name="citation_author_institution" content="Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China">
<meta name="citation_author" content="Ran You">
<meta name="citation_author_institution" content="Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China">
<meta name="citation_author" content="Lingfeng Diao">
<meta name="citation_author_institution" content="Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China">
<meta name="citation_author" content="Chendong Wang">
<meta name="citation_author_institution" content="Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China">
<meta name="citation_author" content="Zeyu Yu">
<meta name="citation_author_institution" content="Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China">
<meta name="citation_author" content="Guowen Yin">
<meta name="citation_author_institution" content="Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China">
<meta name="citation_publication_date" content="2025 Aug 8">
<meta name="citation_volume" content="16">
<meta name="citation_firstpage" content="1501">
<meta name="citation_doi" content="10.1007/s12672-025-03363-9">
<meta name="citation_pmid" content="40779236">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334396/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334396/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334396/pdf/12672_2025_Article_3363.pdf">
<meta name="description" content="To demonstrate the potential benefits of additional transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) after the failure of first-line systemic treatment (ST). This retrospective single-center study was conducted ...">
<meta name="og:title" content="Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="To demonstrate the potential benefits of additional transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) after the failure of first-line systemic treatment (ST). This retrospective single-center study was conducted ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334396/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12334396">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1007/s12672-025-03363-9"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12672_2025_Article_3363.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12334396%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12334396/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12334396/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334396/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-discon.png" alt="Discover Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Discover Oncology" title="Link to Discover Oncology" shape="default" href="https://doi.org/10.1007/s12672-025-03363-9" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Discov Oncol</button></div>. 2025 Aug 8;16:1501. doi: <a href="https://doi.org/10.1007/s12672-025-03363-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1007/s12672-025-03363-9</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Discov%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Discov%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Discov%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Discov%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Qingyu Xu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Qingyu Xu</span></h3>
<div class="p">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qingyu Xu</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leng%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Bin Leng</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Bin Leng</span></h3>
<div class="p">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leng%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Bin Leng</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22You%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ran You</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ran You</span></h3>
<div class="p">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22You%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ran You</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Diao%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Lingfeng Diao</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Lingfeng Diao</span></h3>
<div class="p">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Diao%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lingfeng Diao</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Chendong Wang</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Chendong Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chendong Wang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Zeyu Yu</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Zeyu Yu</span></h3>
<div class="p">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zeyu Yu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yin%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Guowen Yin</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Guowen Yin</span></h3>
<div class="p">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yin%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Guowen Yin</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Interventional Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 25; Accepted 2025 Jul 31; Collection date 2025 Dec.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12334396  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40779236/" class="usa-link">40779236</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background &amp; aims</h3>
<p id="Par1">To demonstrate the potential benefits of additional transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) after the failure of first-line systemic treatment (ST).</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">This retrospective single-center study was conducted between January 2020 and December 2022 on patients with advanced HCC who failed to respond to initial first-line ST. Patients who had previously undergone TACE were excluded. Eligible patients underwent on-demand TACE in addition to ST and were followed until death or until March 2023. The duration of response was recorded. Overall survival (OS) was calculated from the date of failure of first-line ST to the date of death or last follow-up. The primary outcomes were OS and safety, and the secondary outcomes were time to progression (TTP) and objective response rate (ORR).</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">In total, 18 patients were included; 8 patients had failed to respond to lenvatinib or sorafenib monotherapy, and 10 had failed to respond to a combination therapy. The most common progression pattern was the development of new intrahepatic lesions. Salvage treatment consisted of 16 triple therapies and 2 dual therapies, including TACE. The median duration of follow-up was 9.5 months. The median OS from the start of second-line treatment was 24 months. The median TTP was 3.5 months. The ORR was 55.6%, and disease control was achieved in 94.4% of patients. Treatment-related adverse events were common but acceptable.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions</h3>
<p id="Par4">Patients with advanced HCC who face significant treatment challenges could potentially benefit from the addition of TACE to second-line ST.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Transarterial chemoembolization plus systemic treatment, Advanced hepatocellular carcinoma, Second-line option</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par39">Hepatocellular carcinoma (HCC) is a highly prevalent and deadly form of cancer. The majority of patients with HCC present with intermediate- to advanced-stage disease at initial diagnosis; at these stages, individual patients may benefit from transplantation. In such cases, systemic treatment (ST) and transarterial chemoembolization (TACE) are commonly employed as palliative therapies, particularly for Barcelona Clinic Liver Cancer stage B and C (BCLC-B/C) HCC.</p>
<p id="Par40">ST, which mainly refers to molecular targeted therapeutics (MTTs) and immune checkpoint inhibitors (ICIs), is the first-line treatment option for BCLC-C HCC [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Atezolizumab plus bevacizumab, as well as the “STRIDE” regimen, have replaced sorafenib as the preferred first-line options; lenvatinib has also shown comparable survival benefits [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>–<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Despite significant improvements, the median progression-free survival (PFS) remains modest, ranging from 3.78 to 7.4 months, and the median time to progression (TTP) ranges from 2.8 to 8.9 months. Tumor lesions that do not respond or become refractory to ST exist, with an overall response rate (ORR) ranging from 20.1 to 35.4%. In such cases, sequential treatment patterns involving first-line, second-line, and subsequent treatment options have shown potential efficacy. Multiple phase III or Ib/II clinical trials have provided efficacy data for four single agents and one combination therapy approved as second-line strategies, with ongoing studies focusing on ICI-based combination regimens [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>–<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. However, only evidence of the treatment migration after sorafenib has been established. The median overall survival (OS) and TTP in these cases have been unsatisfactory (10.6 and 3.2 months, respectively, with regorafenib) compared to placebo. ST-related adverse events (AEs) have also attracted attention. Scientific evidence for any drug to be used after lenvatinib or ICIs is currently lacking.</p>
<p id="Par41">TACE has been globally adopted as the standard of care for patients with BCLC-B HCC, leading to a median OS of over 30 months, largely owing to its high ORR [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>–<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Promising results have also been observed in a population of patients with BCLC-C predominantly receiving TACE monotherapy [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. According to the theory of synergistic effects, the addition of TACE to ST has been extensively studied in the first-line setting to improve treatment efficacy. Although this combination appears to offer potential benefits, conflicting results have been reported when compared to ST monotherapy [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. The STAH trial showed that compared to sorafenib alone, sorafenib plus TACE improved TTP, PFS, and disease control rate (DCR) in patients with advanced HCC, but it could not significantly improve the OS [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Similar negative results were observed in the SILIUS trial [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. In contrast, the LAUNCH study suggested that compared to lenvatinib alone, lenvatinib plus TACE could further improve the OS, PFS, and ORR [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. Similar positive results were reported in a real-world study [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. However, limited information is available regarding the results of ST plus TACE in the second-line setting. Very few preclinical studies on the combination of regorafenib and TACE have been reported, although prior TACE and other locoregional therapies have been frequently encountered [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>].</p>
<p id="Par42">The present study aimed to demonstrate the potential benefits of incorporating TACE for advanced HCC after the failure of first-line ST.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Patient selection</h3>
<p id="Par43">This retrospective, single-armed, observational study was conducted in accordance with the Declaration of Helsinki and its later amendments and was approved by the hospital ethics committee. The requirement of obtaining written informed consent from the participants was waived owing to the retrospective design of the study. Consecutive patients with advanced HCC between January 2020 and December 2022 who were treated at a single center were reviewed. Advanced HCC cases encompassed BCLC-C HCC cases, and BCLC-B HCC cases that were deemed primarily unsuitable for TACE [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>].</p>
<p id="Par44">The study had the following patient inclusion criteria: (a) age ≥ 18 years, (b) initial advanced HCC or recurrent advanced HCC after radical therapy, (c) failure of first-line ST, and (d) availability of at least one feasible response evaluation according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. The exclusion criteria were: (a) prior locoregional therapy, (b) denial or unsuitability to undergo TACE (Child-Pugh class C; Eastern Cooperative Oncology Group score &gt; 1; complete portal vein obstruction; hepatic-portal arteriovenous fistula), (c) systemic chemotherapy, (d) inconsistent radiological data, (e) loss to follow-up, and (f) severe comorbidity.</p>
<p id="Par45">Failure of first-line ST was defined as disease progression and discontinuation after receiving any therapy based on proven first-line options, except systemic chemotherapy. In the second-line setting, ST plus TACE was defined as any therapy based on proven or emerging first- or second-line options (such as camrelizumab plus apatinib) combined with at least one session of TACE [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>].</p></section><section id="Sec4"><h3 class="pmc_sec_title">TACE procedure</h3>
<p id="Par46">Conventional TACE (cTACE) or drug-eluting beads TACE (DEB-TACE) procedures were performed by two interventional radiologists with over 10 years of experience in endovascular procedures using a standardized technique. On-demand TACE was repeated in case of radiologic evidence of viable tumors. However, in cases of contraindications or when the tumors showed refractoriness to further treatment, TACE was discontinued.</p></section><section id="Sec5"><h3 class="pmc_sec_title">ICI and MTT administration</h3>
<p id="Par47">All the approved ICIs and MTTS available in the hospital were used according to the guidelines based on the standard dose and frequency protocols. ICI monotherapy was not allowed in the first-line setting but it was permitted in the second-line setting. Dose adjustments, interruptions, or discontinuations were based on disease response and the occurrence of toxicity. ICIs were typically administrated three days after TACE and a minimum of two full cycles of treatment was required. Oral MTTs were routinely interrupted during the TACE procedure period.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Follow-up and outcome assessments</h3>
<p id="Par48">Each patient was regularly followed up at intervals of 4–8 weeks. The last follow-up date recorded was March 7, 2023. During these visits, each patient underwent contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) every 6–8 weeks. The imaging results were examined by two independent diagnostic radiologists with more than five years of experience in diagnostic imaging. In case of discrepancies in the measurements, a consensus was reached through a discussion between the radiologists. Tumor response was assessed according to the mRECIST.</p>
<p id="Par49">OS was defined as the time interval from the date of failure of first-line ST to the date of death or last follow-up. TTP was recorded separately from the date of each treatment migration. AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</p></section><section id="Sec7"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par50">Data analysis and figure construction were performed using GraphPad Prism 7.0 (GraphPad Software Inc., San Diego, CA, USA) and Origin 2022 (OriginLab, Northampton, MA, USA). Categorical variables were expressed as frequencies and percentages, and continuous variables were reported as median and range. ANOVA was used for comparisons, with <em>P</em> &lt; 0.05 considered statistically significant. Kaplan–Meier analysis was used to demonstrate the PFS and OS.</p></section></section><section id="Sec8"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec9"><h3 class="pmc_sec_title">Baseline patient characteristics</h3>
<p id="Par51">A total of 18 patients were eligible for analysis (Fig. <a href="#Fig1" class="usa-link">1</a>). The baseline characteristics of the patients are summarized in Table <a href="#Tab1" class="usa-link">1</a>. The median age of the patients was 52.5 (range, 29–80) years, and only one patient was female. Hepatitis B virus (HBV) was detected in 17 (94.4%) patients, and cirrhosis was detected in 13 (72.2%) patients. In total, 12 (66.7%) patients were diagnosed with BCLC-C, with 5 of them showing metastasis in the lungs or lymph nodes. Thirteen HCC cases exceeded the Milan criteria for transplantation. The median duration of follow-up time was 9.5 (range, 2–30) months.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12334396_12672_2025_3363_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e927/12334396/b2a249df1871/12672_2025_3363_Fig1_HTML.jpg" loading="lazy" id="d33e661" height="451" width="709" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow chart of patient selection</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Patient baseline characteristics before first-line therapy</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Characteristics</th>
<th align="left" colspan="1" rowspan="1">
<em>N</em>(%)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Age, y. Median (range)</td>
<td align="left" colspan="1" rowspan="1">52.5 (29–80)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Gender</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="left" colspan="1" rowspan="1">17(94.4%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">1(5.6%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Hepatitis B virus</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Absent</td>
<td align="left" colspan="1" rowspan="1">1(5.6%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Present</td>
<td align="left" colspan="1" rowspan="1">17(94.4%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Cirrhosis</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Absent</td>
<td align="left" colspan="1" rowspan="1">5(27.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Present</td>
<td align="left" colspan="1" rowspan="1">13(72.2%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Child-Pugh class</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">17(94.4%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">B</td>
<td align="left" colspan="1" rowspan="1">1(5.6%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">ECOG Performance status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">13(72.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">5(27.8%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">BCLC Stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">B</td>
<td align="left" colspan="1" rowspan="1">6(33.3%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">12(66.7%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Up-to-seven</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt; 7</td>
<td align="left" colspan="1" rowspan="1">13(72.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≤ 7</td>
<td align="left" colspan="1" rowspan="1">5(27.8%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Macroscopic portal vein invasion</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Absent</td>
<td align="left" colspan="1" rowspan="1">8(44.4%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Present</td>
<td align="left" colspan="1" rowspan="1">10(55.6%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Extrahepatic spread</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Absent</td>
<td align="left" colspan="1" rowspan="1">13(72.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Present</td>
<td align="left" colspan="1" rowspan="1">5(27.8%)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">AFP, ng/ml</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 400</td>
<td align="left" colspan="1" rowspan="1">5(27.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 400</td>
<td align="left" colspan="1" rowspan="1">8(44.4%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">5(27.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Duration of follow-up</td>
<td align="left" colspan="1" rowspan="1">9.5(2–30)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p20"><p>ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; UK, unknown</p></div></div></section></section><section id="Sec10"><h3 class="pmc_sec_title">Options and results of first-line treatment</h3>
<p id="Par54">Lenvatinib-based therapies were administrated to a total of eight patients, with five patients receiving monotherapy (Patients 1, 6, 8, 11, and 16) and three patients receiving a combination of lenvatinib with other therapies (Patients 3, 4, and 14). Five patients received ICIs in combination with bevacizumab or its biosimilar (Patients 5, 7, 9, 10, and 18). Sorafenib monotherapy was administered to three patients (Patients 12, 13, and 15), and in one patient, it was combined with atezolizumab (Patient 17). Only one patient received a reported combination of ICI and a tyrosine-kinase inhibitor (Patient 2).</p>
<p id="Par55">The BCLC stage of two patients (Patients 13 and 14) progressed from stage B to C owing to new extrahepatic spread. The intrahepatic tumor burden aggravated in two patients (Patients 15 and 17). Patient 5 developed portal vein tumor thrombus after treatment. All five described progression patterns were observed, including 10 with new intrahepatic lesions (NIH), 5 with intrahepatic growth (IHG), 2 with new extrahepatic lesions (NEH), 1 with extrahepatic growth (EHG), and 1 with new vascular invasion (nVI; Fig. <a href="#Fig2" class="usa-link">2</a>) [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. The median time from the commencement of first-line ST to progression was 60.5 (range, 28–777) days. Detailed results are shown in Table <a href="#Tab2" class="usa-link">2</a>.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12334396_12672_2025_3363_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e927/12334396/4231ad970d86/12672_2025_3363_Fig2_HTML.jpg" loading="lazy" id="d33e1566" height="552" width="709" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Colored dot plots of five types of progression patterns upon failure of response to first-line therapies</p></figcaption></figure><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Selection criteria 1</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">PatientNO.</th>
<th align="left" colspan="1" rowspan="1">First-line treatment</th>
<th align="left" colspan="1" rowspan="1">BCLC Stage</th>
<th align="left" colspan="1" rowspan="1">Up-to-seven</th>
<th align="left" colspan="1" rowspan="1">New-onset PVI or EHS</th>
<th align="left" colspan="1" rowspan="1">TTP, d</th>
<th align="left" colspan="1" rowspan="1">Progression patterns, IHG/NIH/EHG/NEH/nVI (BCLCp)</th>
<th align="left" colspan="1" rowspan="1">Second-line systemic options</th>
<th align="left" colspan="1" rowspan="1">TACE sessions</th>
<th align="left" colspan="1" rowspan="1">TACE type</th>
<th align="left" colspan="1" rowspan="1">Other locoregional therapies</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">31</td>
<td align="left" colspan="1" rowspan="1">NIH (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+camrelizumab</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Camrelizumab+apatinib</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">68</td>
<td align="left" colspan="1" rowspan="1">NIH (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Camrelizumab+apatinib</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+sintilimab</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">51</td>
<td align="left" colspan="1" rowspan="1">NIH (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+camrelizumab</td>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+envafolimab</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">75</td>
<td align="left" colspan="1" rowspan="1">NIH (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+camrelizumab</td>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Atezolizumab+bevacizumab</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">PVI</td>
<td align="left" colspan="1" rowspan="1">65</td>
<td align="left" colspan="1" rowspan="1">NIH+nVI (p-C2)</td>
<td align="left" colspan="1" rowspan="1">Atezolizumab+bevacizumab</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">105</td>
<td align="left" colspan="1" rowspan="1">NIH (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC; Surgery</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">Sintilimab+bevacizumab biosimilar</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">56</td>
<td align="left" colspan="1" rowspan="1">IHG (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Regorafenib+tislelizumab</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">28</td>
<td align="left" colspan="1" rowspan="1">IHG (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+camrelizumab</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">9</td>
<td align="left" colspan="1" rowspan="1">Atezolizumab+bevacizumab</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">53</td>
<td align="left" colspan="1" rowspan="1">IHG (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Atezolizumab+bevacizumab</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">Sintilimab+bevacizumab biosimilar</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">EHG</td>
<td align="left" colspan="1" rowspan="1">Regorafenib+tislelizumab</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib</td>
<td align="left" colspan="1" rowspan="1">B</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">56</td>
<td align="left" colspan="1" rowspan="1">NIH (p-B)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+camrelizumab</td>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC; Surgery</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">Sorafenib</td>
<td align="left" colspan="1" rowspan="1">B</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">32</td>
<td align="left" colspan="1" rowspan="1">IHG (p-B)</td>
<td align="left" colspan="1" rowspan="1">Camrelizumab</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">13</td>
<td align="left" colspan="1" rowspan="1">Sorafenib</td>
<td align="left" colspan="1" rowspan="1">B → C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">EHS</td>
<td align="left" colspan="1" rowspan="1">777</td>
<td align="left" colspan="1" rowspan="1">NEH</td>
<td align="left" colspan="1" rowspan="1">Sorafenib+tislelizumab</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+tislelizumab</td>
<td align="left" colspan="1" rowspan="1">B → C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">EHS</td>
<td align="left" colspan="1" rowspan="1">54</td>
<td align="left" colspan="1" rowspan="1">NEH</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+tislelizumab</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">15</td>
<td align="left" colspan="1" rowspan="1">Sorafenib</td>
<td align="left" colspan="1" rowspan="1">B</td>
<td align="left" colspan="1" rowspan="1">≤ 7 → &gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">131</td>
<td align="left" colspan="1" rowspan="1">NIH (p-B)</td>
<td align="left" colspan="1" rowspan="1">Sorafenib+tislelizumab</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib</td>
<td align="left" colspan="1" rowspan="1">B</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">431</td>
<td align="left" colspan="1" rowspan="1">NIH (p-B)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+camrelizumab</td>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">HAIC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">Sorafenib+atezolizumab</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">≤ 7 → &gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">68</td>
<td align="left" colspan="1" rowspan="1">NIH (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Lenvatinib+atezolizumab</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">cTACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">18</td>
<td align="left" colspan="1" rowspan="1">Sintilimab+bevacizumab biosimilar</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">&gt;7</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">167</td>
<td align="left" colspan="1" rowspan="1">IHG (p-C1)</td>
<td align="left" colspan="1" rowspan="1">Sintilimab+bevacizumab biosimilar</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">DEB-TACE</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
</tbody>
</table></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="3" colspan="1">Patient NO.</th>
<th align="left" colspan="5" rowspan="1">Response Assessment</th>
<th align="left" colspan="4" rowspan="1">AFP, ng/ml</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Targeted lesions and new lesions</th>
<th align="left" colspan="2" rowspan="1">Non-targeted lesions</th>
<th align="left" rowspan="2" colspan="1">New lesions</th>
<th align="left" rowspan="2" colspan="1">Overall response</th>
<th align="left" rowspan="2" colspan="1">Before first-line therapy</th>
<th align="left" rowspan="2" colspan="1">Upon first-line therapy failure</th>
<th align="left" rowspan="2" colspan="1">Lowest level after second-line therapy</th>
<th align="left" rowspan="2" colspan="1">P</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Intrahepatic lesions</th>
<th align="left" colspan="1" rowspan="1">Vascular invasion</th>
<th align="left" colspan="1" rowspan="1">Extrahepatic lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">72949</td>
<td align="left" colspan="1" rowspan="1">39783</td>
<td align="left" colspan="1" rowspan="1">0.9018</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">5600.2</td>
<td align="left" colspan="1" rowspan="1">6846</td>
<td align="left" colspan="1" rowspan="1">768.3</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">11356</td>
<td align="left" colspan="1" rowspan="1">7486</td>
<td align="left" colspan="1" rowspan="1">2052</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">3000</td>
<td align="left" colspan="1" rowspan="1">34771</td>
<td align="left" colspan="1" rowspan="1">2998</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">102</td>
<td align="left" colspan="1" rowspan="1">121.4</td>
<td align="left" colspan="1" rowspan="1">32.71</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">278</td>
<td align="left" colspan="1" rowspan="1">512.9</td>
<td align="left" colspan="1" rowspan="1">118.8</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">18826</td>
<td align="left" colspan="1" rowspan="1">5989</td>
<td align="left" colspan="1" rowspan="1">3.77</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">120000</td>
<td align="left" colspan="1" rowspan="1">120000</td>
<td align="left" colspan="1" rowspan="1">120000</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">9</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">212</td>
<td align="left" colspan="1" rowspan="1">140.3</td>
<td align="left" colspan="1" rowspan="1">16.54</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">98.6</td>
<td align="left" colspan="1" rowspan="1">36.33</td>
<td align="left" colspan="1" rowspan="1">4.02</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">CR</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">8.65</td>
<td align="left" colspan="1" rowspan="1">10.04</td>
<td align="left" colspan="1" rowspan="1">9.94</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">92.98</td>
<td align="left" colspan="1" rowspan="1">28.9</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">13</td>
<td align="left" colspan="1" rowspan="1">PD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PD</td>
<td align="left" colspan="1" rowspan="1">25.79</td>
<td align="left" colspan="1" rowspan="1">29.96</td>
<td align="left" colspan="1" rowspan="1">59.63</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">7.82</td>
<td align="left" colspan="1" rowspan="1">4.14</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">15</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">363.6</td>
<td align="left" colspan="1" rowspan="1">154.1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">PR</td>
<td align="left" colspan="1" rowspan="1">UK</td>
<td align="left" colspan="1" rowspan="1">1518</td>
<td align="left" colspan="1" rowspan="1">474</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">15.1</td>
<td align="left" colspan="1" rowspan="1">92.42</td>
<td align="left" colspan="1" rowspan="1">21.55</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">18</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">SD</td>
<td align="left" colspan="1" rowspan="1">63.62</td>
<td align="left" colspan="1" rowspan="1">53.2</td>
<td align="left" colspan="1" rowspan="1">6.02</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec20"><h3 class="pmc_sec_title">Second-line therapies, response assessments</h3>
<p id="Par56">Among the study patients, 16 received triple therapies containing TACE, and 2 patients received dual therapies (Patients 6 and 12). Six patients continued with their original treatment strategies with the addition of TACE; five patients received combinations of ICIs and one patient received monotherapy with lenvatinib. The number of TACE sessions ranged from 2 to 11, with only one patient undergoing two cycles of DEB-TACE (Patient 18). Other locoregional therapies included hepatic artery infusion chemotherapy (HAIC) and palliative resection.</p>
<p id="Par57">Table <a href="#Tab2" class="usa-link">2</a> presents the best responses according to the mRECIST. Among all patients, 10 (55.6%) patients achieved a partial response, whereas no patient achieved complete response. Thus, the objective response rate was 55.6%. In addition, 7 (38.9%) patients experienced stable disease. The DCR was 94.4%. The specific objective responses and their respective durations for each patient are illustrated in Fig. <a href="#Fig3" class="usa-link">3</a>.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12334396_12672_2025_3363_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e927/12334396/24114da85e1b/12672_2025_3363_Fig3_HTML.jpg" loading="lazy" id="d33e1798" height="583" width="709" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Duration of objective response in each patient. The black arrow represents ongoing line treatment, the red circle indicates death, and the green hook represents disease-free survival status after radical surgery</p></figcaption></figure></section><section id="Sec11"><h3 class="pmc_sec_title">Outcomes and AEs</h3>
<p id="Par59">Until the last date of follow-up, eight cases of disease progression and four deaths were observed. The median OS was 24 months, and the median TTP was 21 months (3.5 months among the 8 analyzed patients; Fig. <a href="#Fig4" class="usa-link">4</a>).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e927/12334396/b6e8c974f1d1/12672_2025_3363_Fig4_HTML.jpg" loading="lazy" id="d33e1815" height="571" width="634" alt="Fig. 4"></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier curves show overall survival (OS; <strong>A</strong>) and time to progression (TTP; <strong>B</strong>). The number of patients at risk at several time points is listed in parentheses</p></figcaption></figure><p id="Par60">Postembolization syndrome occurred in 17 (94.4%) patients, and all (100%) patients experienced systemic-related AEs. Among the AEs, grade 1 or 2 events accounted for 72.2%, and grade 3 or 4 AEs accounted for 27.8%. The most common events included transaminase elevation (88.9%), anemia (66.7%) hypothyroidism (44.4%), and hypertension (27.8%; Table <a href="#Tab3" class="usa-link">3</a>). No treatment-related deaths were observed.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Adverse events from any cause</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Variable</th>
<th align="left" colspan="1" rowspan="1">Total</th>
<th align="left" colspan="1" rowspan="1">Grade 1 or 2</th>
<th align="left" colspan="1" rowspan="1">Grade 3 or 4</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">PES</td>
<td align="center" colspan="1" rowspan="1">17(94.4%)</td>
<td align="center" colspan="1" rowspan="1">17(94.4%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ST-related AEs</td>
<td align="center" colspan="1" rowspan="1">18(100.0%)</td>
<td align="center" colspan="1" rowspan="1">13(72.2%)</td>
<td align="center" colspan="1" rowspan="1">5(27.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Transaminase elevation</td>
<td align="center" colspan="1" rowspan="1">16(88.9%)</td>
<td align="center" colspan="1" rowspan="1">14(77.8%)</td>
<td align="center" colspan="1" rowspan="1">2(11.1%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Thrombocytopenia</td>
<td align="center" colspan="1" rowspan="1">2(11.1%)</td>
<td align="center" colspan="1" rowspan="1">2(11.1%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hypoalbuminemia</td>
<td align="center" colspan="1" rowspan="1">3(16.7%)</td>
<td align="center" colspan="1" rowspan="1">3(16.7%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hyperbilirubinemia</td>
<td align="center" colspan="1" rowspan="1">9(50.0%)</td>
<td align="center" colspan="1" rowspan="1">9(50.0%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Leukopenia</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Neutropenia</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Anemia</td>
<td align="center" colspan="1" rowspan="1">12(66.7%)</td>
<td align="center" colspan="1" rowspan="1">11(61.1%)</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rash or inflammatory dermatitis</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pain</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Decreased appetite</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">1(5.6%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hypothyroidism</td>
<td align="center" colspan="1" rowspan="1">8(44.4%)</td>
<td align="center" colspan="1" rowspan="1">8(44.4%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hypertension</td>
<td align="center" colspan="1" rowspan="1">5(27.8%)</td>
<td align="center" colspan="1" rowspan="1">2(11.1%)</td>
<td align="center" colspan="1" rowspan="1">3(16.7%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HFSR</td>
<td align="center" colspan="1" rowspan="1">2(11.1%)</td>
<td align="center" colspan="1" rowspan="1">2(11.1%)</td>
<td align="center" colspan="1" rowspan="1">0(0.0%)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p43"><p>PES, postembolization syndrome; ST, systemic treatment; AEs, adverse events; HFSR, hand-foot skin reaction</p></div></div></section></section></section><section id="Sec12"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par61">Currently, there is growing support from various trials for the combination of TACE and ST as the most dominant treatment option in the first-line setting for unresectable HCC. However, in the second-line setting for advanced HCC, the clinical benefit of this combination has not yet been adequately and systematically evaluated. In this single-center case series study involving 18 patients with HCC, almost all real-life conditions were represented, including various tumor characteristics, first-line treatment protocols, and progression patterns. The combination of TACE and ST revealed promising results, with a 24-month OS observed from the date of failure of first-line ST, along with manageable complications. The TTP was achieved in 8 (44.4%) patients, with a median TTP of 3.5 months. Notably, 55.6% of patients with advanced HCC showed an objective response when treated with regorafenib combined with TACE, and 94.4% of patients achieved disease control. These preliminary outcomes indicate that patients with advanced HCC, even those facing formidable challenges, may potentially benefit from the addition of TACE to ST.</p>
<p id="Par62">Four types of proven first-line treatment options were administrated to 14 patients in the study. Previous studies have often focused on specific subgroups with a particular treatment regimen, such as atezolizumab plus bevacizumab [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. In terms of methodology, this study provides a general understanding of second-line therapy, whereas Shao et al. provided a more targeted understanding. The OS for second-line therapy in this study was 24 months, whereas the study by Shao et al. reported an OS of 8 months. However, the results cannot be directly compared owing to the lack of separate results for patients undergoing TACE in the latter study. The decision-making process for treatment selection is influenced by factors such as financial burden, physicians’ preferences, and patients’ choices in real-life practice. In China, physicians generally adhere to guidelines such as the BCLC guidelines or the China National Liver Cancer guidelines for HCC when making treatment-related decisions. As this study is a small case series, conducting a cross-sectional study based on a large database, such as a national platform, may yield more comprehensive epidemiological results.</p>
<p id="Par63">Advanced HCC exhibits substantial heterogeneity in terms of progression patterns, salvage treatment patterns, and post-progression prognosis. In this study, the most common progression pattern was NIH, followed by IHG, NEH, and EHG/nVI. This finding differs from the results reported by Reig et al. and Talbot et al. [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. The differences may be attributed to the demographics of the patient cohorts, particularly the prevalence of HBV infection in the current study. In contrast, most of the patients in the other two studies had hepatitis C virus infection or no viral infection. HBV and HCV act on different stages of the carcinogenic process, with HBV initiating the process and HCV promoting its development. Consequently, in the current study, the residual normal liver tissue was more likely to develop NIH lesions in the 18 patients, while IHG was more frequent in the other two studies.</p>
<p id="Par64">The choice of first-line ST also varies among studies (multiple types of ST vs. sorafenib vs. ICIs). Post-progression prognosis is influenced by specific progression patterns and salvage treatment strategies, as previously mentioned [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. In this study, TACE combined with ST achieved a post-progression OS of 24 months, which is superior to the OS reported by previous studies and confirms the consolidative effect of subsequent treatment. Although no self-controlled analysis was conducted based on the abovementioned patterns, it is believed that the outcomes of patients in different groups would differ. There have been some suggestions regarding the design of second-line trials and clinical practice, and the addition of TACE has been highlighted as an approach that directly targets intrahepatic solid tumors.</p>
<p id="Par65">It is worth mentioning that one patient (Patient 11) achieved successful conversion therapy after not achieving a response with lenvatinib monotherapy (Fig. <a href="#Fig5" class="usa-link">5</a>). In this case, the tumor was primarily unresectable from a surgical perspective, with risk factors including insufficient future liver remnant and a low chance of achieving R0 resection. While lenvatinib is generally effective, with a good ORR of 24.1%, it seemed ineffective for this patient. However, for some patients, lenvatinib may provide long-term tumor control and improve OS.</p>
<figure class="fig xbox font-sm" id="Fig5"><h3 class="obj_head">Fig. 5.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12334396_12672_2025_3363_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e927/12334396/fd3c71921456/12672_2025_3363_Fig5_HTML.jpg" loading="lazy" id="d33e1825" height="264" width="709" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Successful conversion therapy of Patient 11</p></figcaption></figure><p id="Par66">Currently, the combination of ICIs and MTTs seems to be a better treatment option compared to single agents alone [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. The most important considerations in conversion therapy are ORR and mitigation, including tumor progression rate and the time, duration, and depth of remission. TACE and HAIC have shown superiority in this case, as they contribute to a lower tumor progression rate; rapid onset of response, which helps to reduce the exposure time of conversion therapy so as to reduce the incidence of adverse reactions; deeper remission, which is undoubtedly more conducive than subsequent treatment; and longer duration of remission. These factors provide a longer window period for subsequent treatment options. Numerous research studies have provided evidence for the application of locoregional treatment combined with ST in conversion therapy [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>, <a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>].</p>
<p id="Par67">To date, several clinical trials have been conducted to investigate the use of TACE plus regorafenib with/without ICIs as a second-line therapy for HCC [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. These studies have demonstrated acceptable results in terms of both safety and efficacy. Similarly, the current study showed promising outcomes with no severe complications. It is important to note that when comparing the results of a single cohort with other studies, differences may be attributed to variations in evaluation criteria, sample sizes, and intervention doses.</p>
<p id="Par68">This study has several limitations that should be acknowledged. Firstly, it is a retrospective, case series study conducted at a single center, which may limit the generalizability of the findings to other populations. The conclusions drawn from this study must be interpreted with caution and considered as preliminary evidence. Secondly, over half of the patients did not reach the study endpoints, and therefore, the outcomes may be subject to potential bias. Continued follow-up is necessary to obtain a more comprehensive understanding of the long-term outcomes. Thirdly, the TACE procedure itself is heterogeneous. The comparison between cTACE and DEB-TACE remains controversial, and the differences in the efficacy between these two techniques could introduce bias in the results. Moreover, the presence of technical bias in the TACE procedures cannot be ruled out. The lack of a control group, such as a single-agent ST group, and subgroup analysis is another limitation of the study. Considering these limitations, future trials are needed to validate the findings of our study.</p>
<p id="Par69">In conclusion, this case series study preliminarily demonstrates the promising benefit of the addition of TACE to ST in the second-line setting for advanced HCC involving almost all real-life conditions. The results provide a basis for exploring the efficacy of the combined approach. Future research directions include:1.Multi-center, prospective, randomized controlled trials to further validate the efficacy and safety of the protocol, providing high-level clinical evidence for clinical application.2.Further investigation of TACE protocols (cTACE and DEB-TACE) and different types of systemic treatment regimens to improve efficacy and reduce adverse reactions.3.Research on biomarkers to predict patients who may benefit, which will help personalize treatment and explore the mechanisms underlying the benefits of combination therapy.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We would like to thank MogoEdit (https://www.mogoedit.com) for its English editing during the preparation of this manuscript.</p>
<section id="FPar3"><h3 class="pmc_sec_title">Dual publication</h3>
<p id="Par74">Not applicable.</p></section><section id="FPar4"><h3 class="pmc_sec_title">Permission to use third-party material</h3>
<p id="Par75">Not applicable.</p></section></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>TACE</dt>
<dd><p id="Par5">Transarterial chemoembolization</p></dd>
<dt>HCC</dt>
<dd><p id="Par6">Hepatocellular carcinoma</p></dd>
<dt>ST</dt>
<dd><p id="Par7">Systemic treatment</p></dd>
<dt>OS</dt>
<dd><p id="Par8">Overall survival</p></dd>
<dt>TTP</dt>
<dd><p id="Par9">Time to progression</p></dd>
<dt>ORR</dt>
<dd><p id="Par10">Objective response rate</p></dd>
<dt>BCLC</dt>
<dd><p id="Par11">Barcelona clinic liver cancer</p></dd>
<dt>MTTs</dt>
<dd><p id="Par12">Molecular targeted therapeutics</p></dd>
<dt>ICIs</dt>
<dd><p id="Par13">Immune checkpoint inhibitors</p></dd>
<dt>PFS</dt>
<dd><p id="Par14">Progression-free survival</p></dd>
<dt>AEs</dt>
<dd><p id="Par15">Adverse events</p></dd>
<dt>DCR</dt>
<dd><p id="Par16">Disease control rate</p></dd>
<dt>mRECIST</dt>
<dd><p id="Par17">Modified response evaluation criteria in solid tumors</p></dd>
<dt>cTACE</dt>
<dd><p id="Par18">Conventional TACE</p></dd>
<dt>DEB-TACE</dt>
<dd><p id="Par19">Drug-eluting beads TACE</p></dd>
<dt>CT</dt>
<dd><p id="Par20">Contrast-enhanced computed tomography</p></dd>
<dt>MRI</dt>
<dd><p id="Par21">Magnetic resonance imaging</p></dd>
<dt>CTCAE</dt>
<dd><p id="Par22">Common terminology criteria for adverse events</p></dd>
<dt>HBV</dt>
<dd><p id="Par23">Hepatitis B virus</p></dd>
<dt>NIH</dt>
<dd><p id="Par24">New intrahepatic lesion (s)</p></dd>
<dt>IHG</dt>
<dd><p id="Par25">Intrahepatic growth</p></dd>
<dt>NEH</dt>
<dd><p id="Par26">New extrahepatic lesion (s)</p></dd>
<dt>EHG</dt>
<dd><p id="Par27">Extrahepatic growth</p></dd>
<dt>nVI</dt>
<dd><p id="Par28">New vascular invasion</p></dd>
<dt>HAIC</dt>
<dd><p id="Par29">Hepatic artery infusion chemotherapy</p></dd>
<dt>ECOG</dt>
<dd><p id="Par30">Eastern cooperative oncology group</p></dd>
<dt>AFP</dt>
<dd><p id="Par31">Alpha-fetoprotein</p></dd>
<dt>UK</dt>
<dd><p id="Par32">Unknown</p></dd>
<dt>BCLCp</dt>
<dd><p id="Par33">BCLC upon progression</p></dd>
<dt>PR</dt>
<dd><p id="Par34">Partial response</p></dd>
<dt>SD</dt>
<dd><p id="Par35">Stable disease</p></dd>
<dt>PD</dt>
<dd><p id="Par36">Progressive disease</p></dd>
<dt>PES</dt>
<dd><p id="Par37">Postembolization syndrome</p></dd>
<dt>HFSR</dt>
<dd><p id="Par38">Hand-foot skin reaction</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Qingyu Xu and Bin Leng contributed equally to this work. Guowen Yin, Ran You designed the study, performed the experiments, and wrote the manuscript. Bin Leng and Ran You conducted examinations. Chendong Wang, Zeyu Yu and Lingfeng Diao collected the data. Bin Leng and Ran You provided hepatological advice and edited the manuscript. Guowen Yin revised the manuscript for important intellectual content.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>Project for the Development of Young Professional Technical Talent in Jiangsu Cancer Hospital (2017YQL-12).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>Correspondence and reasonable requests for original dataset should be addressed to the corresponding author.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar5"><h3 class="pmc_sec_title">Ethical approval and consent to participate</h3>
<p id="Par76">The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments and was approved by the Ethics Committee of Jiangsu Cancer Hospital. The consents from participants were waived in this retrospective study, which was approved by our ethics committee (KY-2023-025). We declared that patient data was maintained with confidentiality and all the process complies with the requirements of the Ethics Committee of the Jiangsu Cancer Hospital.</p></section><section id="FPar1"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par77">All authors have read the journal’s policies and submitted their manuscripts in accordance with these policies. All authors agree with the content of the article and have submitted it, with prior approval from the department head obtained before submission.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par78">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div>
<div class="fn p" id="fn2"><p>Qingyu Xu and Bin Leng contributed equally as the joint first authors.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Ran You, Email: youran@njmu.edu.cn.</p>
<p>Guowen Yin, Email: jsnjygw@njmu.edu.cn.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2021.11.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8866082/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34801630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reig%20M,%20Forner%20A,%20Rimola%20J,%20et%20al.%20BCLC%20strategy%20for%20prognosis%20prediction%20and%20treatment%20recommendation:%20the%202022%20update.%20J%20Hepatol.%202022;76(3):681%E2%80%9393." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
</cite> [<a href="https://doi.org/10.1056/NEJMoa0708857" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18650514/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Llovet%20JM,%20Ricci%20S,%20Mazzaferro%20V,%20et%20al.%20Sorafenib%20in%20advanced%20hepatocellular%20carcinoma.%20N%20Engl%20J%20Med.%202008;359(4):378%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Kudo M, Finn RS, Qin S, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(18)30207-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29433850/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kudo%20M,%20Finn%20RS,%20Qin%20S,%20et%20al.%20Lenvatinib%20versus%20Sorafenib%20in%20first-line%20treatment%20of%20patients%20with%20unresectable%20hepatocellular%20carcinoma:%20a%20randomised%20phase%203%20non-inferiority%20trial.%20Lancet.%202018;391(10126):1163%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1915745" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32402160/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Finn%20RS,%20Qin%20S,%20Ikeda%20M,%20et%20al.%20Atezolizumab%20plus%20bevacizumab%20in%20unresectable%20hepatocellular%20carcinoma.%20N%20Engl%20J%20Med.%202020;382(20):1894%E2%80%93905." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.
</cite> [<a href="https://doi.org/10.1056/EVIDoa2100070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38319892/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Abou-Alfa%20GK,%20Lau%20G,%20Kudo%20M,%20et%20al.%20Tremelimumab%20plus%20durvalumab%20in%20unresectable%20hepatocellular%20carcinoma.%20NEJM%20Evid.%202022;1(8):EVIDoa2100070." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on Sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(16)32453-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27932229/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bruix%20J,%20Qin%20S,%20Merle%20P,%20et%20al.%20Regorafenib%20for%20patients%20with%20hepatocellular%20carcinoma%20who%20progressed%20on%20Sorafenib%20treatment%20(RESORCE):%20a%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial.%20Lancet.%202017;389(10064):56%E2%80%9366." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after Sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(18)30937-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30665869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20AX,%20Kang%20YK,%20Yen%20CJ,%20et%20al.%20Ramucirumab%20after%20Sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20and%20increased%20%CE%B1-fetoprotein%20concentrations%20(REACH-2):%20a%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial.%20Lancet%20Oncol.%202019;20(2):282%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1717002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7523244/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Abou-Alfa%20GK,%20Meyer%20T,%20Cheng%20AL,%20et%20al.%20Cabozantinib%20in%20patients%20with%20advanced%20and%20progressing%20hepatocellular%20carcinoma.%20N%20Engl%20J%20Med.%202018;379(1):54%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as Second-Line therapy in patients from Asia with advanced hepatocellular carcinoma: A randomized, Double-Blind, phase III trial. J Clin Oncol. 2023;41(7):1434–43.
</cite> [<a href="https://doi.org/10.1200/JCO.22.00620" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9995104/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36455168/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qin%20S,%20Chen%20Z,%20Fang%20W,%20et%20al.%20Pembrolizumab%20versus%20placebo%20as%20Second-Line%20therapy%20in%20patients%20from%20Asia%20with%20advanced%20hepatocellular%20carcinoma:%20A%20randomized,%20Double-Blind,%20phase%20III%20trial.%20J%20Clin%20Oncol.%202023;41(7):1434%E2%80%9343." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as Second-Line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, Double-Blind, phase III trial. J Clin Oncol. 2020;38(3):193–202.
</cite> [<a href="https://doi.org/10.1200/JCO.19.01307" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31790344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Finn%20RS,%20Ryoo%20BY,%20Merle%20P,%20et%20al.%20Pembrolizumab%20as%20Second-Line%20therapy%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20in%20KEYNOTE-240:%20A%20randomized,%20Double-Blind,%20phase%20III%20trial.%20J%20Clin%20Oncol.%202020;38(3):193%E2%80%93202." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2020.4564" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7530824/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33001135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yau%20T,%20Kang%20YK,%20Kim%20TY,%20et%20al.%20Efficacy%20and%20safety%20of%20nivolumab%20plus%20ipilimumab%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20previously%20treated%20with%20sorafenib:%20the%20checkmate%20040%20randomized%20clinical%20trial.%20JAMA%20Oncol.%202020;6(11):e204564." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):871–3.
</cite> [<a href="https://doi.org/10.1093/annonc/mdy510" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30715202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vogel%20A,%20Cervantes%20A,%20Chau%20I,%20et%20al.%20Hepatocellular%20carcinoma:%20ESMO%20clinical%20practice%20guidelines%20for%20diagnosis,%20treatment%20and%20follow-up.%20Ann%20Oncol.%202019;30(5):871%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>[Guidelines for diagnosis and treatment of primary liver cancer in China. (2019 edition)]. Zhonghua Gan Zang Bing Za Zhi. 2020. 28(2): 112–128.</cite> [<a href="https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32164061/" class="usa-link">PubMed</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Okusaka T, Kasugai H, Shioyama Y, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009;51(6):1030–6.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2009.09.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19864035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Okusaka%20T,%20Kasugai%20H,%20Shioyama%20Y,%20et%20al.%20Transarterial%20chemotherapy%20alone%20versus%20transarterial%20chemoembolization%20for%20hepatocellular%20carcinoma:%20a%20randomized%20phase%20III%20trial.%20J%20Hepatol.%202009;51(6):1030%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.
</cite> [<a href="https://doi.org/10.1053/jhep.2003.50047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12540794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Llovet%20JM,%20Bruix%20J.%20Systematic%20review%20of%20randomized%20trials%20for%20unresectable%20hepatocellular%20carcinoma:%20chemoembolization%20improves%20survival.%20Hepatology.%202003;37(2):429%E2%80%9342." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58.
</cite> [<a href="https://doi.org/10.1038/s41392-022-01235-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9905571/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36750721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20HD,%20Li%20HL,%20Huang%20MS,%20et%20al.%20Transarterial%20chemoembolization%20with%20PD-(L)1%20inhibitors%20plus%20molecular%20targeted%20therapies%20for%20hepatocellular%20carcinoma%20(CHANCE001).%20Signal%20Transduct%20Target%20Ther.%202023;8(1):58." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus Sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424–32.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(18)30078-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29631810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kudo%20M,%20Ueshima%20K,%20Yokosuka%20O,%20et%20al.%20Sorafenib%20plus%20low-dose%20cisplatin%20and%20fluorouracil%20hepatic%20arterial%20infusion%20chemotherapy%20versus%20Sorafenib%20alone%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20(SILIUS):%20a%20randomised,%20open%20label,%20phase%203%20trial.%20Lancet%20Gastroenterol%20Hepatol.%202018;3(6):424%E2%80%9332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019;70(4):684–91.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2018.11.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30529387/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Park%20JW,%20Kim%20YJ,%20Kim%20DY,%20et%20al.%20Sorafenib%20with%20or%20without%20concurrent%20transarterial%20chemoembolization%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma:%20the%20phase%20III%20STAH%20trial.%20J%20Hepatol.%202019;70(4):684%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Ju S, Zhou C, Yang C, et al. Apatinib plus camrelizumab with/without chemoembolization for hepatocellular carcinoma: A Real-World experience of a single center. Front Oncol. 2021;11:835889.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.835889" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8841670/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35174073/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ju%20S,%20Zhou%20C,%20Yang%20C,%20et%20al.%20Apatinib%20plus%20camrelizumab%20with/without%20chemoembolization%20for%20hepatocellular%20carcinoma:%20A%20Real-World%20experience%20of%20a%20single%20center.%20Front%20Oncol.%202021;11:835889." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as First-Line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117–27.
</cite> [<a href="https://doi.org/10.1200/JCO.22.00392" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35921605/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Peng%20Z,%20Fan%20W,%20Zhu%20B,%20et%20al.%20Lenvatinib%20combined%20with%20transarterial%20chemoembolization%20as%20First-Line%20treatment%20for%20advanced%20hepatocellular%20carcinoma:%20A%20phase%20III,%20randomized%20clinical%20trial%20(LAUNCH).%20J%20Clin%20Oncol.%202023;41(1):117%E2%80%9327." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus Sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–501.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2019-318934" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7398460/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31801872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kudo%20M,%20Ueshima%20K,%20Ikeda%20M,%20et%20al.%20Randomised,%20multicentre%20prospective%20trial%20of%20transarterial%20chemoembolisation%20(TACE)%20plus%20Sorafenib%20as%20compared%20with%20TACE%20alone%20in%20patients%20with%20hepatocellular%20carcinoma:%20TACTICS%20trial.%20Gut.%202020;69(8):1492%E2%80%93501." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Wang H, Xiao W, Han Y, et al. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy. J Gastrointest Oncol. 2022;13(3):1248–54.
</cite> [<a href="https://doi.org/10.21037/jgo-22-395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9274068/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35837179/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20H,%20Xiao%20W,%20Han%20Y,%20et%20al.%20Study%20on%20safety%20and%20efficacy%20of%20regorafenib%20combined%20with%20transcatheter%20arterial%20chemoembolization%20in%20the%20treatment%20of%20advanced%20hepatocellular%20carcinoma%20after%20first-line%20targeted%20therapy.%20J%20Gastrointest%20Oncol.%202022;13(3):1248%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Han Y, Cao G, Sun B, et al. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol. 2021;21(1):393.
</cite> [<a href="https://doi.org/10.1186/s12876-021-01967-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8529854/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34670512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Han%20Y,%20Cao%20G,%20Sun%20B,%20et%20al.%20Regorafenib%20combined%20with%20transarterial%20chemoembolization%20for%20unresectable%20hepatocellular%20carcinoma:%20a%20real-world%20study.%20BMC%20Gastroenterol.%202021;21(1):393." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Kudo M. A new treatment option for Intermediate-Stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE. Liver Cancer. 2019;8(5):299–311.
</cite> [<a href="https://doi.org/10.1159/000502905" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6872999/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31768341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kudo%20M.%20A%20new%20treatment%20option%20for%20Intermediate-Stage%20hepatocellular%20carcinoma%20with%20high%20tumor%20burden:%20initial%20lenvatinib%20therapy%20with%20subsequent%20selective%20TACE.%20Liver%20Cancer.%202019;8(5):299%E2%80%93311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
</cite> [<a href="https://doi.org/10.1055/s-0030-1247132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12268942/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20175033/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lencioni%20R,%20Llovet%20JM.%20Modified%20RECIST%20(mRECIST)%20assessment%20for%20hepatocellular%20carcinoma.%20Semin%20Liver%20Dis.%202010;30(1):52%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, Open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003–11.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-2571" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33087333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20J,%20Shen%20J,%20Gu%20S,%20et%20al.%20Camrelizumab%20in%20combination%20with%20apatinib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20(RESCUE):%20A%20nonrandomized,%20Open-label,%20phase%20II%20trial.%20Clin%20Cancer%20Res.%202021;27(4):1003%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013;58(6):2023–31.
</cite> [<a href="https://doi.org/10.1002/hep.26586" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23787822/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reig%20M,%20Rimola%20J,%20Torres%20F,%20et%20al.%20Postprogression%20survival%20of%20patients%20with%20advanced%20hepatocellular%20carcinoma:%20rationale%20for%20second-line%20trial%20design.%20Hepatology.%202013;58(6):2023%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Talbot T, D’Alessio A, Pinter M, et al. Progression patterns and therapeutic sequencing following immune checkpoint Inhibition for hepatocellular carcinoma: an international observational study. Liver Int. 2023;43(3):695–707.
</cite> [<a href="https://doi.org/10.1111/liv.15502" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10947007/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36577703/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Talbot%20T,%20D%E2%80%99Alessio%20A,%20Pinter%20M,%20et%20al.%20Progression%20patterns%20and%20therapeutic%20sequencing%20following%20immune%20checkpoint%20Inhibition%20for%20hepatocellular%20carcinoma:%20an%20international%20observational%20study.%20Liver%20Int.%202023;43(3):695%E2%80%93707." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Chen CT, Feng YH, Yen CJ, et al. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line Atezolizumab and bevacizumab treatment. Hepatol Int. 2022;16(5):1199–207.
</cite> [<a href="https://doi.org/10.1007/s12072-022-10392-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35986846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20CT,%20Feng%20YH,%20Yen%20CJ,%20et%20al.%20Prognosis%20and%20treatment%20pattern%20of%20advanced%20hepatocellular%20carcinoma%20after%20failure%20of%20first-line%20Atezolizumab%20and%20bevacizumab%20treatment.%20Hepatol%20Int.%202022;16(5):1199%E2%80%93207." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and Anti-PD-1 antibody combinations. Liver Cancer. 2021;10(4):320–9.
</cite> [<a href="https://doi.org/10.1159/000514313" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8339461/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34414120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20XD,%20Huang%20C,%20Shen%20YH,%20et%20al.%20Downstaging%20and%20resection%20of%20initially%20unresectable%20hepatocellular%20carcinoma%20with%20tyrosine%20kinase%20inhibitor%20and%20Anti-PD-1%20antibody%20combinations.%20Liver%20Cancer.%202021;10(4):320%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs Sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial. JAMA Oncol. 2019;5(7):953–60.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2019.0250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6512278/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31070690/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20M,%20Li%20Q,%20Zou%20R,%20et%20al.%20Sorafenib%20plus%20hepatic%20arterial%20infusion%20of%20oxaliplatin,%20fluorouracil,%20and%20leucovorin%20vs%20Sorafenib%20alone%20for%20hepatocellular%20carcinoma%20with%20portal%20vein%20invasion:%20A%20randomized%20clinical%20trial.%20JAMA%20Oncol.%202019;5(7):953%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17588359211002720.
</cite> [<a href="https://doi.org/10.1177/17588359211002720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8010824/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33854567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20MK,%20Liang%20RB,%20Zhao%20Y,%20et%20al.%20Lenvatinib,%20toripalimab,%20plus%20hepatic%20arterial%20infusion%20chemotherapy%20versus%20lenvatinib%20alone%20for%20advanced%20hepatocellular%20carcinoma.%20Ther%20Adv%20Med%20Oncol.%202021;13:17588359211002720." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Zou X, Xu Q, You R, Yin G. Efficacy and safety of TACE combined with regorafenib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma after Sorafenib resistance. J Hepatocell Carcinoma. 2023;10:267–79.
</cite> [<a href="https://doi.org/10.2147/JHC.S399874" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9940502/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36815093/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zou%20X,%20Xu%20Q,%20You%20R,%20Yin%20G.%20Efficacy%20and%20safety%20of%20TACE%20combined%20with%20regorafenib%20plus%20PD-1%20inhibitor%20in%20the%20treatment%20of%20hepatocellular%20carcinoma%20after%20Sorafenib%20resistance.%20J%20Hepatocell%20Carcinoma.%202023;10:267%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Correspondence and reasonable requests for original dataset should be addressed to the corresponding author.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Discover Oncology are provided here courtesy of <strong>Springer</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1007/s12672-025-03363-9"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12672_2025_Article_3363.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.8 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12334396/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12334396/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12334396%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334396/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12334396/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12334396/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40779236/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12334396/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40779236/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12334396/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12334396/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="zgqTjgWzToKAcwPotPgJqMpcZdclxaULiAfr9RuKdPfH78hXXnR9V2BumyF9aY2s">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
